Literature DB >> 4065105

The influence of ketamine on both normal and raised intracranial pressure of artificially ventilated animals.

E Pfenninger, W Dick, F W Ahnefeld.   

Abstract

The effect of two different doses of ketamine, 0.5 mg kg-1 body weight, and 2.0 mg kg-1 body weight, on intracranial pressure and cerebral perfusion pressure were investigated in 21 young pigs (26-34 kg) under controlled artificial ventilation. Three groups each containing seven animals were studied: Group 1. Initially normal blood pressure and an intracranial pressure within the normal range (10.7 mmHg). Group 2. Normal blood pressure and increased intracranial pressure caused by inflating an epidural balloon (29.2 mmHg). Group 3. Increased intracranial pressure (32.7 mmHg) and mean arterial pressure reduced by approximately 30% through controlled haemorrhage. There was no increase in intracranial pressure from either normal or initially increased values. This applied to animals with normal blood pressure values and also to those in haemorrhagic shock. This observation can be explained by the lack of an increase in PCO2 under controlled ventilation. During haemorrhagic shock cerebral perfusion pressure fell significantly as a result of the fall in mean arterial pressure. This particularly applied to the 2.0 mg kg-1 dose of ketamine. We therefore consider volume substitution to be essential in this situation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065105

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  2 in total

1.  Ketamine for analgosedative therapy in intensive care treatment of head-injured patients.

Authors:  H Kolenda; A Gremmelt; S Rading; U Braun; E Markakis
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 2.  Ketamine: an update on the first twenty-five years of clinical experience.

Authors:  D L Reich; G Silvay
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.